Headlines about Regenxbio (NASDAQ:RGNX) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Regenxbio earned a daily sentiment score of 0.25 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.1097415965224 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Here are some of the news stories that may have impacted Accern Sentiment Analysis’s rankings:
- Regenxbio (RGNX) Upgraded by BidaskClub to Strong-Buy (americanbankingnews.com)
- Regenxbio Inc (RGNX) Insider Kenneth T. Mills Sells 10,000 Shares (americanbankingnews.com)
- Regenxbio Shows Rising Price Performance With Jump To 93 RS Rating (finance.yahoo.com)
- Regenxbio Inc (RGNX) CFO Vittal Vasista Sells 5,000 Shares (americanbankingnews.com)
- REGENXBIO, Inc. is trading above its 50 day moving average : RGNX-US : December 20, 2017 (finance.yahoo.com)
Several brokerages have commented on RGNX. Raymond James Financial began coverage on shares of Regenxbio in a report on Thursday, October 12th. They issued an “outperform” rating and a $39.00 price objective for the company. Bank of America restated a “buy” rating and issued a $38.00 price objective (up from $33.00) on shares of Regenxbio in a report on Monday, October 9th. Zacks Investment Research upgraded shares of Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a report on Wednesday, October 18th. Chardan Capital restated a “buy” rating on shares of Regenxbio in a report on Monday, December 11th. Finally, BidaskClub upgraded shares of Regenxbio from a “buy” rating to a “strong-buy” rating in a report on Friday. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $42.43.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative net margin of 764.06% and a negative return on equity of 39.33%. The business had revenue of $1.34 million during the quarter. equities analysts predict that Regenxbio will post -2.71 earnings per share for the current fiscal year.
In related news, SVP Curran Simpson sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $29.31, for a total transaction of $58,620.00. Following the completion of the sale, the senior vice president now owns 41,500 shares of the company’s stock, valued at $1,216,365. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Vittal Vasista sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $33.25, for a total transaction of $166,250.00. Following the sale, the chief financial officer now directly owns 92,283 shares of the company’s stock, valued at approximately $3,068,409.75. The disclosure for this sale can be found here. Insiders have sold 104,000 shares of company stock valued at $3,304,546 in the last three months. 17.00% of the stock is owned by insiders.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.